Clements John M, Coignard Fanny, Johnson Ian, Chandler Stephen, Palan Shilpa, Waller Andrew, Wijkmans Jac, Hunter Michael G
British Biotech Pharmaceuticals Ltd., Oxford OX4 6LY, United Kingdom.
Antimicrob Agents Chemother. 2002 Jun;46(6):1793-9. doi: 10.1128/AAC.46.6.1793-1799.2002.
Lipid A is the hydrophobic anchor of lipopolysaccharide (LPS) and forms the major lipid component of the outer monolayer of the outer membrane of gram-negative bacteria. Lipid A is required for bacterial growth and virulence, and inhibition of its biosynthesis is lethal to bacteria. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) is a metalloenzyme that catalyzes the second step in the biosynthesis of lipid A. Inhibitors of LpxC have previously been shown to have antibiotic activities. We have screened a metalloenzyme inhibitor library for antibacterial activities against an Escherichia coli strain with reduced LpxC activity. From this screen, a series of sulfonamide derivatives of the alpha-(R)-amino hydroxamic acids, exemplified by BB-78484 and BB-78485, have been identified as having potent inhibitory activities against LpxC in an in vitro assay. Leads from this series showed gram-negative selective activities against members of the Enterobacteriaceae, Serratia marcescens, Morganella morganii, Haemophilus influenzae, Moraxella catarrhalis, and Burkholderia cepacia. BB-78484 was bactericidal against E. coli, achieving 3-log killing in 4 h at a concentration 4 times above the MIC, as would be predicted for an inhibitor of lipid A biosynthesis. E. coli mutants with decreased susceptibility to BB-78484 were selected. Analysis of these mutants revealed that resistance arose as a consequence of mutations in the fabZ or lpxC genes. These data confirm the antibacterial target of BB-78484 and BB-78485 and validate LpxC as a target for gram-negative selective antibacterials.
脂多糖(LPS)的疏水锚定基团是脂质A,它构成革兰氏阴性菌外膜外单层的主要脂质成分。脂质A是细菌生长和毒力所必需的,抑制其生物合成对细菌是致命的。UDP-3-O-(R-3-羟基肉豆蔻酰基)-N-乙酰葡糖胺脱乙酰酶(LpxC)是一种金属酶,催化脂质A生物合成的第二步。先前已证明LpxC抑制剂具有抗生素活性。我们筛选了一个金属酶抑制剂文库,以寻找对LpxC活性降低的大肠杆菌菌株具有抗菌活性的化合物。通过该筛选,一系列α-(R)-氨基异羟肟酸的磺酰胺衍生物,以BB-78484和BB-78485为例,已被鉴定在体外试验中对LpxC具有强效抑制活性。该系列的先导化合物对肠杆菌科、粘质沙雷氏菌、摩根氏摩根菌、流感嗜血杆菌、卡他莫拉菌和洋葱伯克霍尔德菌的成员表现出革兰氏阴性选择性活性。BB-78484对大肠杆菌具有杀菌作用,在浓度高于最低抑菌浓度(MIC)4倍时,4小时内可实现3个对数级的杀菌效果,这正如对脂质A生物合成抑制剂所预期的那样。筛选出了对BB-78484敏感性降低的大肠杆菌突变体。对这些突变体的分析表明,耐药性是由于fabZ或lpxC基因突变所致。这些数据证实了BB-78484和BB-78485的抗菌靶点,并验证了LpxC作为革兰氏阴性选择性抗菌药物的靶点。